Alexandra Pasut
About Alexandra Pasut
Alexandra Pasut is a Déléguée Hospitalière Immuno-Oncologie at Bristol-Myers Squibb in Aquitaine, France, with extensive experience in pharmaceutical and medical delegation roles.
Current Role at Bristol-Myers Squibb
Alexandra Pasut is currently working at Bristol-Myers Squibb as a Déléguée Hospitalière Immuno-Oncologie in Aquitaine, France. In her current role, she manages relationships with key hospital leaders and promotes innovative immuno-oncology treatments. Part of her responsibilities includes organizing numerous staff meetings and professional gatherings to facilitate information exchange among healthcare specialists.
Previous Positions at Bristol-Myers Squibb
Alexandra Pasut has held multiple roles at Bristol-Myers Squibb. She worked as a Déléguée pharmaceutique UPSA from 2013 to 2015 in Gironde, France. Prior to that, she served as a Déléguée Hospitalière et Spécialiste Neurosciences for eight years, from 2005 to 2013, in the Région de Bordeaux. Her career at the company began as a Déléguée médicale ville from 2004 to 2005 in the same region, making her long-standing association with the company evident.
Experience at VENTIV HEALTH
Before joining Bristol-Myers Squibb, Alexandra Pasut worked at VENTIV HEALTH for five years, from 1998 to 2003. During her tenure at VENTIV HEALTH, she served as a Déléguée médicale in the Région de Bordeaux, France, gaining valuable experience that would later benefit her career in the pharmaceutical industry.
Educational Background
Alexandra Pasut has a diverse educational background. She studied at Ecole supérieure de Commerce de Toulouse, where she completed her Mastère in Management de la Santé from 2001 to 2002. She also earned a DIPLOME NATIONAL DE LA VISITE MEDICALE from MEDISCOLA CCI CHARTRES between 1997 and 1998. Additionally, she holds a Maîtrise de biochimie structurale from Université Paul Sabatier Toulouse, achieved in 1997.
Significant Contributions and Initiatives
Alexandra Pasut has made notable contributions in her field, including promoting the anti-PD1 monoclonal antibody Opdivo to various specialists such as onco-dermatologists, pneumologists, radiotherapists, and hospital pharmacists. She successfully launched Opdivo for bronchial cancer treatment. Alexandra has also played a role in a collaborative innovation project aimed at enhancing patient information in day hospitals.